idiopathic pulmonary fibrosis - lungfibrosis of unknown origine
Conditions
Interventions
twice daily BIBF 1120 orally taken
Sponsors
Boehringer Ingelheim
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Signed Informed Consent consistent with ICH-GCP and local laws prior to trial participation. 2. Patients from trial 1199.34 who completed the 52 weeks treatment period and performed the follow-up visit.
Exclusion criteria
Exclusion criteria: 1. AST, ALT > 1.5 fold ULN; Patients who completed the parent trial with transaminase values > 1.5 fold ULN but 1.5 fold ULN 3. Bleeding risk. 4. Planned major surgery within the next 3 months, including lung transplantation, major abdominal or major intestinal surgery. 5. New major thrombo-embolic events developed after completion of the parent trial. 6.Time period > 12 weeks between Visit 9 of the parent trial and Visit 2 of this study. 7. Usage of any investigational drug after completion of the parent trial or planned usage of a specific investigational drug during the course of this trial. 8. A disease or condition which in the opinion of investigator may put the patient at risk because of participation in this trial or limit the patient*s ability to participate in this trial. 9. Alcohol or drug abuse which in the opinion of the investigator would interfere with trial participation. 10. Pregnant women or women who are breast feeding or of child bearing potential not using two effective methods of birth control (one barrier and one highly effective non-barrier) for at least 1 month prior to Visit 2 and/or not committing to using it until 3 months after end of treatment. 11. Sexually active men not committing to using condoms during participation in the study (except if their partner is not of childbearing potential) and 3 months after the last intake of BIBF 1120.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| long-term safety | — |
Secondary
| Measure | Time frame |
|---|---|
| Absolute and relative change from baseline in FVC and in % predicted FVC; On trial survival (all data collected based on fatal adverse events); Time to first acute IPF exacerbation | — |
Countries
Netherlands
Outcome results
None listed